Basic Stats
| CIK | 1333170 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to NxStage Medical, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| December 23, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NxStage Medical, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 67072V103 (CUSIP Number) December 13, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| March 5, 2019 |
NXTM / NxStage Medical, Inc. 15-12G 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 000-51567 NxStage Medical, Inc. (Exact name of registrant as specified in |
|
| February 22, 2019 |
NXTM / NxStage Medical, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 22, 2019 Registration No. |
|
| February 22, 2019 |
NXTM / NxStage Medical, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 22, 2019 Registration No. |
|
| February 22, 2019 |
NXTM / NxStage Medical, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 22, 2019 Registration No. |
|
| February 22, 2019 |
NXTM / NxStage Medical, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 22, 2019 Registration No. |
|
| February 22, 2019 |
NXTM / NxStage Medical, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 22, 2019 Registration No. |
|
| February 22, 2019 |
NXTM / NxStage Medical, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 22, 2019 Registration No. |
|
| February 22, 2019 |
NXTM / NxStage Medical, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 22, 2019 Registration No. |
|
| February 22, 2019 |
NXTM / NxStage Medical, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 22, 2019 Registration No. |
|
| February 22, 2019 |
NXTM / NxStage Medical, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 22, 2019 Registration No. |
|
| February 22, 2019 |
Third Amended and Restated By-Laws of NxStage Medical, Inc. EX-3.2 3 d711615dex32.htm EX-3.2 Exhibit 3.2 THIRD AMENDED AND RESTATED BY-LAWS OF NxSTAGE MEDICAL, INC. ARTICLE I. OFFICES Section 1. The registered office shall be in the City of Wilmington, County of New Castle, State of Delaware. Section 2. The corporation may also have offices at such other places both within and without the State of Delaware as the Board of Directors may from time to time de |
|
| February 22, 2019 |
Amended and Restated Certificate of Incorporation of NxStage Medical, Inc. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NxSTAGE MEDICAL, INC. FIRST: The name of the Corporation is NxStage Medical, Inc. SECOND: The address of the Corporation’s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, 19801. The name of its registered agent at such address is The C |
|
| February 22, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2019 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (C |
|
| February 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 NxStage Medical, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 67072V103 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 14, 2019 |
NXTM / NxStage Medical, Inc. / TIG Advisors, LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 11, 2019 |
NXTM / NxStage Medical, Inc. / VANGUARD GROUP INC Passive Investment nxstagemedicalinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5 )* Name of issuer: NxStage Medical Inc Title of Class of Securities: Common Stock CUSIP Number: 67072V103 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropriate bo |
|
| January 29, 2019 |
Entry into a Material Definitive Agreement 8-K 1 mergerextension8-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2019 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdicti |
|
| November 7, 2018 |
NXTM / NxStage Medical, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-51567 NxStage Medical, Inc. |
|
| October 30, 2018 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2018 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission |
|
| August 7, 2018 |
NXTM / NxStage Medical, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-51567 NxStage Medical, Inc. |
|
| July 30, 2018 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2018 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 18, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2018 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 31, 2018 |
NXTM / NxStage Medical, Inc. SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report NxStage Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 350 Merrimack Street, Lawrence, MA 01843 (Address of Princ |
|
| May 31, 2018 |
NxStage Medical, Inc. Conflict Minerals Report Reporting Year: 2017 This report has been prepared pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended (Rule 13p-1), for the reporting period from January 1, 2017 to December 31, 2017, and is available at the Investor Relations section of our website, www.nxstage.com. Company Overview NxStage Medical, Inc. (NxStage or we) is a |
|
| May 29, 2018 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2018 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission File |
|
| May 10, 2018 |
NXTM / NxStage Medical, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-51567 NxStage Medical, Inc. |
|
| April 26, 2018 |
NXTM / NxStage Medical, Inc. DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 16, 2018 |
EXHIBIT 21 Subsidiaries of the Registrant Name Jurisdiction of Incorporation EIR Medical, Inc. |
|
| February 16, 2018 |
EX-10.17 2 nxtm20172131ex1017.htm EXHIBIT 10.17 Non-Employee Director Compensation Policy This policy describes the compensation payable to Directors of NxStage Medical, Inc. (“NxStage”) who are not employees of NxStage (or its subsidiaries) and have not been employees of NxStage (or its subsidiaries) within the preceding 12 months. All other Directors will not receive compensation from NxStage fo |
|
| February 16, 2018 |
NXTM / NxStage Medical, Inc. 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-51567 NxStage Medical, Inc. |
|
| February 14, 2018 |
NXTM / NxStage Medical, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 9, 2018 |
NXTM / NxStage Medical, Inc. / VANGUARD GROUP INC Passive Investment nxstagemedicalinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4 )* Name of issuer: NxStage Medical Inc Title of Class of Securities: Common Stock CUSIP Number: 67072V103 Date of Event Which Requires Filing of this Statement: December 31, 2017 Check the appropriate bo |
|
| November 8, 2017 |
NXTM / NxStage Medical, Inc. 10-Q - NXTM Q3 2017 FORM 10-Q (Quarterly Report) Document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-51567 NxStage Medical, Inc. |
|
| October 27, 2017 |
Submission of Matters to a Vote of Security Holders Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2017 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Co |
|
| October 19, 2017 |
8-K 1 a101917draft8konftc.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2017 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdict |
|
| October 6, 2017 |
Submission of Matters to a Vote of Security Holders 8-K 1 form8-k2017sayonpay.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2017 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdictio |
|
| September 22, 2017 |
DEFM14A 1 d410078ddefm14a.htm DEFM14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| September 6, 2017 |
PREM 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Pr |
|
| August 11, 2017 |
NXTM / NxStage Medical, Inc. / GILDER GAGNON HOWE & CO LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 3)* NxStage Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67072V103 (CUSIP Number) July 31, 2017 (Date of Event which Requires Filing of t |
|
| August 8, 2017 |
NxStage Medical 10-Q (Quarterly Report) Document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-51567 NxStage Medical, Inc. |
|
| August 7, 2017 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| August 7, 2017 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2017 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Comm |
|
| August 7, 2017 |
EX-3.1 3 d436075dex31.htm EXHIBIT 3.1 Exhibit 3.1 SECOND AMENDED AND RESTATED BY-LAWS OF NXSTAGE MEDICAL, INC. TABLE OF CONTENTS ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 2 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 2 1.10 Nomination of Directors 3 1.11 Notice of Business |
|
| August 7, 2017 |
THIRD AMENDMENT TO JOSEPH E. TURK, JR. EMPLOYMENT AGREEMENT EX-10.2 5 d436075dex102.htm EXHIBIT 10.2 Exhibit 10.2 THIRD AMENDMENT TO JOSEPH E. TURK, JR. EMPLOYMENT AGREEMENT WHEREAS, NxStage Medical, Inc. (the “Company”) and Joseph E. Turk, Jr. (“Executive”) entered into an employment agreement dated as of October 18, 2005, as amended (the “Agreement”); WHEREAS, the Company and Executive desire to further amend the Agreement on the terms set forth in this |
|
| August 7, 2017 |
NxStage Reports Second Quarter Financial Results Exhibit 99.1 Exhibit 99.1 NxStage Reports Second Quarter Financial Results ? Company and Fresenius Medical Care Announce Definitive Agreement under which Fresenius Medical Care Will Acquire NxStage for $30.00 Per Share ? Revenue Increases to $96.2 million, up 4% from Q2?FY16 ? Company Advances Pipeline with Launch of NxGen Hemodialysis System in NxStage Kidney Care LAWRENCE, Mass., Aug. 7, 2017 /P |
|
| August 7, 2017 |
EX-2.1 2 d436075dex21.htm EXHIBIT 2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among FRESENIUS MEDICAL CARE HOLDINGS, INC. BROADWAY RENAL SERVICES, INC. and NxSTAGE MEDICAL, INC. dated as of August 7, 2017 TABLE OF CONTENTS ARTICLE I THE MERGER Section 1.1 The Merger 2 Section 1.2 Closing; Effective Time 2 Section 1.3 Governing Documents; Directors and Officers 2 Section 1.4 Conversion of S |
|
| August 7, 2017 |
THIRD AMENDMENT TO JEFFREY H. BURBANK EMPLOYMENT AGREEMENT EX-10.1 4 d436075dex101.htm EXHIBIT 10.1 Exhibit 10.1 THIRD AMENDMENT TO JEFFREY H. BURBANK EMPLOYMENT AGREEMENT WHEREAS, NxStage Medical, Inc. (the “Company”) and Jeffrey H. Burbank (“Executive”) entered into an employment agreement dated as of October 19, 2005, as amended (the “Agreement”); WHEREAS, the Company and Executive desire to further amend the Agreement on the terms set forth in this Th |
|
| August 7, 2017 |
Exhibit 99.2 Exhibit 99.2 Press Release Media Contact Fresenius Medical Care Group Joachim Weith T +49 6172 609-2101 [email protected] Fresenius Medical Care North America Katherine Dobbs T +1 781 699-9039 [email protected] Contact for Analysts and Investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com NxStage Contact Kristen K. She |
|
| August 7, 2017 |
THIRD AMENDMENT TO JEFFREY H. BURBANK EMPLOYMENT AGREEMENT Exhibit 10.1 Exhibit 10.1 THIRD AMENDMENT TO JEFFREY H. BURBANK EMPLOYMENT AGREEMENT WHEREAS, NxStage Medical, Inc. (the ?Company?) and Jeffrey H. Burbank (?Executive?) entered into an employment agreement dated as of October 19, 2005, as amended (the ?Agreement?); WHEREAS, the Company and Executive desire to further amend the Agreement on the terms set forth in this Third Amendment to the Agreeme |
|
| August 7, 2017 |
NxStage Reports Second Quarter Financial Results Exhibit 99.1 Exhibit 99.1 NxStage Reports Second Quarter Financial Results ? Company and Fresenius Medical Care Announce Definitive Agreement under which Fresenius Medical Care Will Acquire NxStage for $30.00 Per Share ? Revenue Increases to $96.2 million, up 4% from Q2?FY16 ? Company Advances Pipeline with Launch of NxGen Hemodialysis System in NxStage Kidney Care LAWRENCE, Mass., Aug. 7, 2017 /P |
|
| August 7, 2017 |
EX-99.2 7 d436075dex992.htm EXHIBIT 99.2 Exhibit 99.2 Press Release Media Contact Fresenius Medical Care Group Joachim Weith T +49 6172 609-2101 [email protected] Fresenius Medical Care North America Katherine Dobbs T +1 781 699-9039 [email protected] Contact for Analysts and Investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com Nx |
|
| August 7, 2017 |
Exhibit 2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among FRESENIUS MEDICAL CARE HOLDINGS, INC. BROADWAY RENAL SERVICES, INC. and NxSTAGE MEDICAL, INC. dated as of August 7, 2017 TABLE OF CONTENTS ARTICLE I THE MERGER Section 1.1 The Merger 2 Section 1.2 Closing; Effective Time 2 Section 1.3 Governing Documents; Directors and Officers 2 Section 1.4 Conversion of Shares; Conversion of Merge |
|
| August 7, 2017 |
THIRD AMENDMENT TO JOSEPH E. TURK, JR. EMPLOYMENT AGREEMENT EX-10.2 5 d436075dex102.htm EXHIBIT 10.2 Exhibit 10.2 THIRD AMENDMENT TO JOSEPH E. TURK, JR. EMPLOYMENT AGREEMENT WHEREAS, NxStage Medical, Inc. (the “Company”) and Joseph E. Turk, Jr. (“Executive”) entered into an employment agreement dated as of October 18, 2005, as amended (the “Agreement”); WHEREAS, the Company and Executive desire to further amend the Agreement on the terms set forth in this |
|
| August 7, 2017 |
DEFA14A 1 d436075d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2017 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdictio |
|
| August 7, 2017 |
Exhibit 3.1 Exhibit 3.1 SECOND AMENDED AND RESTATED BY-LAWS OF NXSTAGE MEDICAL, INC. TABLE OF CONTENTS ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 2 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 2 1.10 Nomination of Directors 3 1.11 Notice of Business at Annual Meetings 5 1.12 |
|
| May 31, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report NxStage Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 350 Merrimack Street, Lawrence, MA 01843 (Address of Princ |
|
| May 31, 2017 |
NxStage Medical, Inc. Conflict Minerals Report Reporting Year: 2016 Exhibit NxStage Medical, Inc. Conflict Minerals Report Reporting Year: 2016 This report has been prepared pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended (Rule 13p-1), for the reporting period from January 1, 2016 to December 31, 2016, and is available at the Investor Relations section of our website, www.nxstage.com . Company Overview NxStage Medical, Inc. (NxStage or |
|
| May 26, 2017 |
Amendment to Amended and Restated By-laws of NxStage Medical, Inc. Exhibit Amendment to Amended and Restated By-laws of NxStage Medical, Inc. Section 1.9 of NxStage?s Amended and Restated By-laws is amended as follows, with deletions indicated by strike-throughs and additions indicated by underlining: 1.9 Action at Meeting . When a quorum is present at any meeting, any matter other than the election of directors to be voted upon by the stockholders at such meetin |
|
| May 26, 2017 |
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2017 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commis |
|
| May 9, 2017 |
NxStage Medical 10-Q - NXSTAGE MEDICAL INC. (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-51567 NxStage Medical, Inc. |
|
| May 9, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 q12017earningsform8-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2017 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction |
|
| May 9, 2017 |
NXSTAGE REPORTS FIRST QUARTER FINANCIAL RESULTS EX-99 2 a20170331-10earningsrelease.htm EXHIBIT 99 NXSTAGE REPORTS FIRST QUARTER FINANCIAL RESULTS • Revenue Increases to $96.8 million, up 9% from Q1'FY16 • Company Reaffirms Total Revenue Guidance and Profitability for 2017 • Company Continues to Advance NxGen Hemodialysis System and Innovative Pipeline LAWRENCE, Mass., May 9, 2017, -NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical techno |
|
| April 28, 2017 |
NxStage Medical 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2017 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Comm |
|
| April 27, 2017 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 14, 2017 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 28, 2017 |
NxStage Medical 10-K - NXSTAGE MEDICAL INC. (Annual Report) Document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-51567 NxStage Medical, Inc. |
|
| February 28, 2017 |
NxStage Medical 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2017 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (C |
|
| February 28, 2017 |
NxStage Reports Fourth Quarter and Full-Year 2016 Financial Results Document NxStage Reports Fourth Quarter and Full-Year 2016 Financial Results Highlights: ? Full-Year Revenue Increases to $366 million , up 9% from 2015 ? Full-Year Home Revenue Increases to $209 million , up over 14% from 2015 ? Full-Year Operating Income from Products Business More than Doubles to $23 million ? Outlook for 2017 Includes Strong Revenue Growth and Total Company Profitability ? Company Continues to Target Introduction of Peritoneal Dialysis System at End of 2017 LAWRENCE, Mass. |
|
| February 14, 2017 |
NXTM / NxStage Medical, Inc. / Flynn James E Passive Investment SC 13G/A 1 e615749sc13ga-nxstage.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 5) * NxStage Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67072V103 (CUSIP Number) December 3 |
|
| February 14, 2017 |
NXTM / NxStage Medical, Inc. / GILDER GAGNON HOWE & CO LLC - SC 13G/A Passive Investment SC 13G/A 1 v458519sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 2)* NxStage Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67072V103 (CUSIP Number) December 31, 2016 |
|
| February 10, 2017 |
NxStage Medical 3G/A (Passive Acquisition of More Than 5% of Shares) nxstagemedicalinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3 )* Name of issuer: NxStage Medical Inc Title of Class of Securities: Common Stock CUSIP Number: 67072V103 Date of Event Which Requires Filing of this Statement: December 31, 2016 Check the appropriate bo |
|
| February 6, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 4 Under the Securities Exchange Act of 1934 NxStage Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 69404D108 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| November 3, 2016 |
NxStage Medical 10-Q (Quarterly Report) 10-Q 1 nxtm20160930-10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition perio |
|
| November 3, 2016 |
NxStage Medical 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2016 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Co |
|
| November 3, 2016 |
Document NXSTAGE REPORTS THIRD QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR REVENUE GUIDANCE AND CUTS NET LOSS GUIDANCE IN HALF ? Q3'16 Revenue and Net Loss Better than Guidance Ranges ? Home Revenue Increases to $53. |
|
| November 3, 2016 |
NXTM / NxStage Medical, Inc. / RS INVESTMENT MANAGEMENT CO LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NxStage Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67072V103 (CUSIP Number) July 31, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| August 4, 2016 |
NxStage Medical 10-Q (Quarterly Report) Document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-51567 NxStage Medical, Inc. |
|
| August 4, 2016 |
THIRD AMENDMENT TO SECOND AMENDED AND RESTATED NATIONAL SERVICE PROVIDER AGREEMENT EX-10.1 2 nxtm20160630ex101.htm EXHIBIT 10.1 Exhibit 10.1 Confidential portions of this Exhibit, denoted by bracketed asterisks, have been omitted and filed separately with the Securities and Exchange Commission in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. THIRD AMENDMENT TO SECOND AMENDED AND RESTATED NATIONAL SERVICE PROVIDER AGREEMENT This Third Amendment (this “Third Amend |
|
| August 4, 2016 |
NXSTAGE REPORTS SECOND QUARTER FINANCIAL RESULTS AND RAISES FULL-YEAR REVENUE GUIDANCE Document NXSTAGE REPORTS SECOND QUARTER FINANCIAL RESULTS AND RAISES FULL-YEAR REVENUE GUIDANCE ? Revenue Increases to $92. |
|
| August 4, 2016 |
NxStage Medical 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2016 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Comm |
|
| July 19, 2016 |
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2016 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commi |
|
| June 27, 2016 |
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2016 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commi |
|
| June 13, 2016 |
NxStage Medical 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2016 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commi |
|
| June 1, 2016 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2016 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission File |
|
| May 31, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report NxStage Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 350 Merrimack Street, Lawrence, MA 01843 (Address of Princ |
|
| May 31, 2016 |
NxStage Medical, Inc. Conflict Minerals Report Reporting Year: 2015 Exhibit NxStage Medical, Inc. Conflict Minerals Report Reporting Year: 2015 This report has been prepared pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended (Rule 13p-1), for the reporting period from January 1, 2015 to December 31, 2015, and is available at the Investor Relations section of our website, www.nxstage.com . Company Overview NxStage Medical, Inc. (NxStage or |
|
| May 4, 2016 |
NxStage Medical 10-Q (Quarterly Report) 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-51567 NxStage Medical, Inc. |
|
| May 4, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2016 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission File |
|
| May 4, 2016 |
NXSTAGE REPORTS FIRST QUARTER FINANCIAL RESULTS 8-K NXSTAGE REPORTS FIRST QUARTER FINANCIAL RESULTS ? Revenue Increases to $89.2 million , up 12% from Q1'15 ? Home Revenue Increases to $49.5 million , up 14% from Q1'15 ? Operating Income from Products Business Increases to $6.2 million ? Total Revenue Guidance for 2016 Moves to High End of Previous Guidance Range LAWRENCE, Mass., May 4, 2016 , -NxStage Medical, Inc. (Nasdaq: NXTM), a leading me |
|
| April 28, 2016 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 16, 2016 |
NXTM / NxStage Medical, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 16, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* NXSTAGE MEDICAL, INC. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 67072V103 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 12, 2016 |
NXTM / NxStage Medical, Inc. / GILDER GAGNON HOWE & CO LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 1)* NxStage Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67072V103 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing |
|
| February 12, 2016 |
NxStage Medical NXSTAGE MEDICAL, INC. (Passive Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NxStage Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67072V103 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 11, 2016 |
NXTM / NxStage Medical, Inc. / VANGUARD GROUP INC Passive Investment nxstagemedicalinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2 )* Name of issuer: NxStage Medical Inc Title of Class of Securities: Common Stock CUSIP Number: 67072V103 Date of Event Which Requires Filing of this Statement: December 31, 2015 Check the appropriate bo |
|
| February 10, 2016 |
NxStage Reports Record Fourth Quarter and Full-Year 2015 Revenue 8-K NxStage Reports Record Fourth Quarter and Full-Year 2015 Revenue Highlights: ? Full-Year Revenue Increases to $336 million , up 11% from 2014 ? Full-Year Home Revenue Increases to $183 million , up 16% from 2014 ? Full-Year Operating Income from Products Business Increases to $9 million ? Company Highlights Significant Product Introductions for the Next Three Years ? For Third Consecutive Year, Company Targets 15% Annual Home Revenue Growth LAWRENCE, Mass. |
|
| February 10, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2016 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commis |
|
| February 3, 2016 |
NXTM / NxStage Medical, Inc. / FEINBERG LARRY N - AMENDMENT NO. 3 Passive Investment SC 13G/A 1 n16172392.htm AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 3) Under the Securities Exchange Act of 1934 NxStage Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67072V103 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| November 3, 2015 |
NxStage Medical 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2015 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commiss |
|
| November 3, 2015 |
NXSTAGE REPORTS RECORD THIRD QUARTER FINANCIAL RESULTS AND INCREASES FINANCIAL GUIDANCE FOR 2015 8-K NXSTAGE REPORTS RECORD THIRD QUARTER FINANCIAL RESULTS AND INCREASES FINANCIAL GUIDANCE FOR 2015 ? Revenue Increases to $86. |
|
| August 6, 2015 |
NxStage Medical 8-K (Current Report/Significant Event) Q2 2015 Earnings Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 6, 2015 |
NXSTAGE REPORTS RECORD SECOND QUARTER FINANCIAL RESULTS AND IMPROVES FINANCIAL GUIDANCE FOR 2015 2015.06.30 EARNINGS RELEASE NXSTAGE REPORTS RECORD SECOND QUARTER FINANCIAL RESULTS AND IMPROVES FINANCIAL GUIDANCE FOR 2015 ? Revenue Increases to $80.3 million , up 8% from Q2'14 ? Home Revenue Increases to $44.8 million , up 16% from Q2'14 ? Products Business Achieves Profitability Goal Ahead of Plan ? Company to Begin Launching Innovative Pipeline Next Year ? Company Renews Blood Tubing Distri |
|
| August 6, 2015 |
ESPP Form S-8 As filed with the Securities and Exchange Commission on August 6, 2015 Registration No. |
|
| July 2, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 4)* NXSTAGE MEDICAL, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 67072V103 (CUSIP Number) December 31, 2014 (Date of Even |
|
| June 1, 2015 |
NXTM / NxStage Medical, Inc. / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NXSTAGE MEDICAL, INC. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 67072V103 (CUSIP Number) May 29, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| June 1, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report NxStage Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 350 Merrimack Street, Lawrence, MA 01843 (Address of Princ |
|
| June 1, 2015 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| June 1, 2015 |
NxStage Medical, Inc. Conflict Minerals Report Reporting Year: 2014 2014 Conflict Minerals Report NxStage Medical, Inc. Conflict Minerals Report Reporting Year: 2014 This report has been prepared pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended (Rule 13p-1), for the reporting period from January 1, 2014 to December 31, 2014, and is available at the Investor Relations section of our website, www.nxstage.com . Company Overview NxStage Med |
|
| May 27, 2015 |
NxStage Medical 8-K (Current Report/Significant Event) 8-K Annual Meeting Results UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 6, 2015 |
NXSTAGE REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS AND EXCEEDS GUIDANCE 2015.03.31 EARNINGS RELEASE NXSTAGE REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS AND EXCEEDS GUIDANCE ? Revenue Increases to $79.5 million , up 10% from Q1'14 ? Home Revenue Increases to $43.5 million , up 19% from Q1'14 ? Company Trending Toward Higher End of Annual Revenue Guidance Range LAWRENCE, Mass., May 6, 2015 , -NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative di |
|
| May 6, 2015 |
NxStage Medical 8-K (Current Report/Significant Event) Q1 2015 Earnings Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 23, 2015 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 11, 2015 |
Shreiner Resignation Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 26, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2015 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission |
|
| February 26, 2015 |
NxStage Reports Record Fourth Quarter and Full-Year 2014 Revenue NxStage Reports Record Fourth Quarter and Full-Year 2014 Revenue Highlights: • Full-Year Total Revenue Increases to $301. |
|
| February 17, 2015 |
NXTM / NxStage Medical, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 10, 2015 |
NXTM / NxStage Medical, Inc. / VANGUARD GROUP INC Passive Investment SC 13G/A 1 nxstagemedicalinc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: NxStage Medical Inc Title of Class of Securities: Common Stock CUSIP Number: 67072V103 Date of Event Which Requires Filing of this Statement: December 31, 2014 Check the appropriate box to designate the rule pursuant |
|
| February 10, 2015 |
NXTM / NxStage Medical, Inc. / GILDER GAGNON HOWE & CO LLC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. )* NxStage Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67072V103 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of |
|
| February 4, 2015 |
NxStage Medical AMENDMENT NO. 3 (Passive Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 3)* Under the Securities Exchange Act of 1934 NxStage Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67072V103 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 4, 2015 |
NXTM / NxStage Medical, Inc. / BLAIR WILLIAM & CO/IL - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 3)* NXSTAGE MEDICAL, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 67072V103 (CUSIP Number) December 31, 2014 (Date of Even |
|
| January 30, 2015 |
NXTM / NxStage Medical, Inc. / FEINBERG LARRY N - SCHEDULE 13G/A, #2 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2) Under the Securities Exchange Act of 1934 NxStage Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67072V103 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| January 13, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2015 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission |
|
| January 13, 2015 |
NxStage Increases Revenue Guidance for the Fourth Quarter and Full-Year 2014 Full-Year 2014 Home Revenue Projected to Increase Approximately 18% LAWRENCE, MA, January 13, 2015 - NxStage® Medical, Inc. |
|
| November 26, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2014 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission |
|
| November 6, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2014 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission |
|
| November 6, 2014 |
NXSTAGE REPORTS RECORD THIRD QUARTER 2014 FINANCIAL RESULTS AND RAISES FULL-YEAR REVENUE GUIDANCE NXSTAGE REPORTS RECORD THIRD QUARTER 2014 FINANCIAL RESULTS AND RAISES FULL-YEAR REVENUE GUIDANCE • Revenue Increases to $75. |
|
| October 29, 2014 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2014 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission |
|
| August 7, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2014 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 7, 2014 |
NXSTAGE REPORTS RECORD SECOND QUARTER 2014 FINANCIAL RESULTS AND INCREASES FULL-YEAR REVENUE GUIDANCE • Revenue Increases to $74. |
|
| June 16, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2014 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 2, 2014 |
NxStage Medical, Inc. Conflict Minerals Report Reporting Year: 2013 NxStage Medical, Inc. Conflict Minerals Report Reporting Year: 2013 This report has been prepared pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended (Rule 13p-1), for the reporting period from January 1, 2013 to December 31, 2013, and is available at the Investor Relations section of our website, www.nxstage.com. Company Overview NxStage Medical, Inc. (NxStage or we) is a |
|
| June 2, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report NxStage Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 350 Merrimack Street, Lawrence, MA 01843 (Address of Princ |
|
| May 30, 2014 |
As filed with the Securities and Exchange Commission on May 30, 2014 Registration No. |
|
| May 30, 2014 |
As filed with the Securities and Exchange Commission on May 30, 2014 Registration No. |
|
| May 30, 2014 |
As filed with the Securities and Exchange Commission on May 30, 2014 Registration No. |
|
| May 28, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2014 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission File |
|
| May 8, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2014 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission File |
|
| May 8, 2014 |
NXSTAGE REPORTS RECORD FIRST QUARTER 2014 FINANCIAL RESULTS AND EXCEEDS GUIDANCE EX-99 2 a20140331earningsrelease.htm PRESS RELEASE NXSTAGE REPORTS RECORD FIRST QUARTER 2014 FINANCIAL RESULTS AND EXCEEDS GUIDANCE • Revenue Increases to $72.2 million, up 17% from Q1'13 • Home Revenue Increases to $36.5 million, up 16% from Q1'13 • Company Trending Toward Higher End of Annual Revenue Guidance Range LAWRENCE, Mass., May 8, 2014, -NxStage Medical, Inc. (Nasdaq: NXTM), a leading ma |
|
| April 28, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2)* Under the Securities Exchange Act of 1934 NxStage Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67072V103 (CUSIP Number) April 24, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| April 24, 2014 |
Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 9, 2014 |
PRE 14A 1 d689173dpre14a.htm PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a party other than the Registrant ¨ Check the appropriate box: þ Preliminary Proxy Statement ¨ Confidential, for Us |
|
| March 3, 2014 |
NxStage Medical 10-K (Annual Report) 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-51567 NxStage Medical, Inc. |
|
| February 27, 2014 |
NxStage Reports Record Fourth Quarter and Full-Year 2013 Financial Results NxStage Reports Record Fourth Quarter and Full-Year 2013 Financial Results Highlights: • Full-Year Revenue Increases to $263. |
|
| February 27, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2014 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission |
|
| February 14, 2014 |
NXTM / NxStage Medical, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 12, 2014 |
NXTM / NxStage Medical, Inc. / VANGUARD GROUP INC Passive Investment nxstagemedicalinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: NxStage Medical Inc Title of Class of Securities: Common Stock CUSIP Number: 67072V103 Date of Event Which Requires Filing of this Statement: December 31, 2013 Check the appropriate bo |
|
| February 7, 2014 |
NXTM / NxStage Medical, Inc. / FEINBERG LARRY N - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) Under the Securities Exchange Act of 1934 NXSTAGE MEDICAL, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 67072V103 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 6, 2014 |
NXTM / NxStage Medical, Inc. / BLAIR WILLIAM & CO/IL - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* NXSTAGE MEDICAL INC (Name of Issuer) Common Stock (Title of Class of Securities) 67072V103 (CUSIP Number) December 31, 2013 (Date of Event |
|
| February 4, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1)* Under the Securities Exchange Act of 1934 NxStage Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67072V103 (CUSIP Number) January 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| January 13, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2014 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission |
|
| January 13, 2014 |
NxStage Increases Revenue Guidance for Fourth Quarter and Full-Year 2013 NxStage Increases Revenue Guidance for Fourth Quarter and Full-Year 2013 LAWRENCE, MA, January 13, 2014 - NxStage® Medical, Inc. |
|
| January 13, 2014 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2014 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission |
|
| January 6, 2014 |
Entry into a Material Definitive Agreement, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2014 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission F |
|
| January 3, 2014 |
NXTM / NxStage Medical, Inc. / MUBADALA DEVELOPMENT CO PJSC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 NxStage Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67072V103 (CUSIP Number) December 26, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| December 30, 2013 |
SCHEDULE 13G JOINT FILING AGREEMENT Exhibit 99.1 SCHEDULE 13G JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (as so amended, the “Schedule 13G”) with respect to the common stock of NxStage Medical, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities E |
|
| December 30, 2013 |
NXTM / NxStage Medical, Inc. / FEINBERG LARRY N - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 NXSTAGE MEDICAL, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 67072V103 (CUSIP Number) December 18, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ¨ |
|
| December 10, 2013 |
NXTM / NxStage Medical, Inc. / WELLS FARGO & COMPANY/MN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) NXSTAGE MEDICAL INC (Name of Issuer) COM (Title of Class of Securities) 67072V103 (CUSIP Number) November 30, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| November 12, 2013 |
Exhibit A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated November 12, 2013 (the “Schedule 13D”), with respect to the common stock, $0. |
|
| November 12, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 9) Under the Securities Exchange Act of 1934 NxStage Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67072V103 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP III LLC Samuel D. Isaly 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name |
|
| November 7, 2013 |
NXSTAGE REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS NXSTAGE REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS • Revenue Increases to $66.9 million, up 9% from Q3'12 • Home Revenue Increases to $33.7 million • Company Announces Regulatory Approval for Nx2me Connected Health Solution • Company Updates Full-Year Guidance for 2013 LAWRENCE, Mass., November 7, 2013, -NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products |
|
| November 7, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2013 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission |
|
| August 8, 2013 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2013 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 25, 2013 |
NXSTAGE REPORTS RECORD REVENUE FOR THE SECOND QUARTER OF FISCAL 2013 NXSTAGE REPORTS RECORD REVENUE FOR THE SECOND QUARTER OF FISCAL 2013 Highlights: • Revenue Increases to $65. |
|
| July 25, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a2013q2earnings8-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2013 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction |
|
| July 2, 2013 |
Exhibit A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated July 2, 2013 (the “Schedule 13D”), with respect to the common stock, $0. |
|
| July 2, 2013 |
SC 13D/A 1 ss180513sc13da.htm AMENDMENT NO. 8 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 8) Under the Securities Exchange Act of 1934 NxStage Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67072V103 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP III LLC Samuel D. Isaly 601 Lexington Avenue, |
|
| June 26, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2013 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 21, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2013 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 24, 2013 |
Submission of Matters to a Vote of Security Holders - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2013 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Commis |
|
| May 21, 2013 |
Entry into a Material Definitive Agreement - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2013 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51567 (Commission File N |
|
| May 2, 2013 |
NXSTAGE REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 NXSTAGE REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS Highlights: • Revenue Increases to $61.6 million, up 8% from Q1’12 • Home Revenue Increases to $31.5 million, up 6% from Q1’12 • Gross Margin Increases to 39%, up from 37% in Q1’12 • Company Announces FDA Clearance of High Flow Capabilities with System One™ • Company Reaffirms Full-Year Outlook for 2013 LAWRENCE, Mass., May |
|
| May 2, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2013 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-51567 (Co |
|
| April 26, 2013 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 25, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2013 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation) (Comm |
|
| March 29, 2013 |
NXTM / NxStage Medical, Inc. / WELLS FARGO & COMPANY/MN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) NXSTAGE MEDICAL INC (Name of Issuer) COM (Title of Class of Securities) 67072V103 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| March 19, 2013 |
NXTM / NxStage Medical, Inc. / Utterberg David S - SC 13D/A Activist Investment SC 13D/A 1 v338668sc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 12)* NxStage Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Se |
|
| March 6, 2013 |
Prospectus Supplement 424(B)(7) Table of Contents Filed Pursuant to Rule 424(b)(7) Registration Statement No. |
|
| March 4, 2013 |
NXTM / NxStage Medical, Inc. / Utterberg David S - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 11)* NxStage Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67072V103 (CUSIP Number) Joh |
|
| February 28, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2013 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation or |
|
| February 28, 2013 |
NxStage Reports Record Fourth Quarter and Full-Year 2012 Financial Results EX-99.01 Exhibit 99.01 NxStage Reports Record Fourth Quarter and Full-Year 2012 Financial Results Highlights: • Full-Year Revenue Increases to $242.1 million, 11% Annual Growth • Full-Year Home Revenue Increases to $123.6 million, 14% Annual Growth • Q4’12 Revenue Increases to a Record $65.0 million, up 14% from Q4’11 • Q4’12 Gross Margin Improves to 39%, up from 37% in Q4’11 • Investments in Dire |
|
| February 20, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 20, 2013 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation or |
|
| February 13, 2013 |
NXTM / NxStage Medical, Inc. / WELLS FARGO & COMPANY/MN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) NXSTAGE MEDICAL INC (Name of Issuer) COM (Title of Class of Securities) 67072V103 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| February 5, 2013 |
NXTM / NxStage Medical, Inc. / BLAIR WILLIAM & CO/IL - SC 13G/A Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* NxStage Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67072V103 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| January 31, 2013 |
Entry into a Material Definitive Agreement - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 30, 2013 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation or organi |
|
| January 25, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 22, 2013 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation or o |
|
| January 25, 2013 |
ROBERT FUNARI JOINS NXSTAGE BOARD OF DIRECTORS Press Release Exhibit 99.1 ROBERT FUNARI JOINS NXSTAGE BOARD OF DIRECTORS LAWRENCE, Mass., January 24, 2013 — NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Robert G. Funari, most recently Chairman of Crescent Healthcare, has been appointed to its Board as an independent director. Mr. Funari served as Chairman and Chief Executive |
|
| January 11, 2013 |
NXTM / NxStage Medical, Inc. / Utterberg David S - AMENDMENT NO. 10 Activist Investment SC 13D/A 1 v331966sc13da.htm AMENDMENT NO. 10 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 10)* NxStage Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Cla |
|
| January 4, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2013 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation or or |
|
| December 20, 2012 |
EX-99 2 e610304ex99.htm Joint Filer Information Names: Deerfield Mgmt L.P., Deerfield Partners, L.P., Deerfield Management Company, L.P., Deerfield International Master Fund, L.P., Deerfield Special Situations Fund, L.P., Deerfield Special Situations International Master Fund, L.P. Address: 780 Third Avenue, 37th Floor New York, NY 10017 Designated Filer: James E. Flynn Issuer and Ticker Symbol: N |
|
| December 14, 2012 |
NXTM / NxStage Medical, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| November 19, 2012 |
NXTM / NxStage Medical, Inc. / Utterberg David S - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 9)* NxStage Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67072V103 (CUSIP Number) John |
|
| November 9, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2012 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation or o |
|
| November 9, 2012 |
JEAN MIXER JOINS NXSTAGE BOARD OF DIRECTORS Exhibit 99.1 JEAN MIXER JOINS NXSTAGE BOARD OF DIRECTORS LAWRENCE, Mass., November 9, 2012 — NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced the appointment of Jean Mixer to its Board of Directors. Ms. Mixer is the Chief Executive Officer of mixerconsulting which focuses on helping organizations grow their business through strategic an |
|
| November 8, 2012 |
NXSTAGE REPORTS RECORD REVENUE FOR THE THIRD QUARTER OF FISCAL 2012 EX-99.1 2 d434298dex991.htm PRESS RELEASE Exhibit 99.1 NXSTAGE REPORTS RECORD REVENUE FOR THE THIRD QUARTER OF FISCAL 2012 Highlights: • Revenue Increases to $61.2 million, up 9% from Q3’11 • Home Revenue Increases to $31.9 million, up 17% from Q3’11 • Gross Margin Increases to 39%, up from 35% in Q3’11 LAWRENCE, Mass., November 8, 2012, —NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufactur |
|
| November 8, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d434298d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2012 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction |
|
| August 15, 2012 |
SC 13D/A 1 ss150980sc13da.htm AMENDMENT NO. 7 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 7) Under the Securities Exchange Act of 1934 NxStage Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67072V103 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP III LLC Samuel D. Isaly 601 Lexington Avenue, |
|
| August 15, 2012 |
Exhibit A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated August 15, 2012 (the “Schedule 13D”), with respect to the common stock, $0. |
|
| August 8, 2012 |
NXSTAGE REPORTS RECORD REVENUE FOR THE SECOND QUARTER OF FISCAL 2012 Press Release Exhibit 99.1 NXSTAGE REPORTS RECORD REVENUE FOR THE SECOND QUARTER OF FISCAL 2012 Highlights: • Revenue Increases to $59.0 million, up 10% from Q2’11 • Home Revenue Increases to $30.7 million, up 14% from Q2’11 • Gross Margin Increases to 38%, up from 35% in Q2’11 • Company Announces European Market Approval for Enhancements to System One LAWRENCE, Mass., August 8, 2012, — NxStage® M |
|
| August 8, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2012 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation or org |
|
| June 28, 2012 |
Correspondence June 28, 2012 Martin James, Senior Assistant Chief Accountant Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| May 31, 2012 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 31, 2012 (May 24, 2012) NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorpo |
|
| May 31, 2012 |
PROSPECTUS CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered (1) Proposed maximum offering price per share (2) Proposed maximum aggregate offering price Amount of registration fee (3) Common Stock, par value $0. |
|
| May 18, 2012 |
NXTM / NxStage Medical, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| May 8, 2012 |
NXSTAGE REPORTS REVENUE FOR THE FIRST QUARTER OF FISCAL 2012; ADVANCES GROWTH STRATEGY EX-99.1 Exhibit 99.1 NXSTAGE REPORTS REVENUE FOR THE FIRST QUARTER OF FISCAL 2012; ADVANCES GROWTH STRATEGY Highlights: • Total Revenue Increases 13% to $57.0 million • Home Revenue Increases 13% to $29.6 million • Company Converts Outstanding Debt to Equity with Strategic Partner, Asahi Kasei Medical Co., Ltd. and Announces System One Collaboration in Japan LAWRENCE, Mass., May 8, 2012, —NxStage® |
|
| May 8, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2012 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation or organi |
|
| April 24, 2012 |
Notice and Proxy Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 12, 2012 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2. Under the Securities Exchange Act of 1934 (Final Amendment) NxStage Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67072V103 (CUSIP Number) Febru |
|
| February 29, 2012 |
Press release Exhibit 99.1 NXSTAGE REPORTS RECORD FOURTH QUARTER AND FULL-YEAR 2011 FINANCIAL RESULTS; REVENUE GROWTH EXCEEDS COMPANY GUIDANCE Highlights: • Full-Year Revenue Increases to $217.3 Million, 21% Annual Growth • Full-Year Home Revenue Increases to $108.5 Million, 27% Annual Growth • Full- Year Gross Margin Improves to 36%, up from 32% for 2010 • Q4’11 Revenue Increases to a Record $57. |
|
| February 29, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 29, 2012 NxSTAGE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-51567 04-3454702 (State or other jurisdiction of incorporation or |
|
| February 14, 2012 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2. Under the Securities Exchange Act of 1934 (Amendment No. 2) NxStage Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67072V103 (CUSIP Number) Decem |
|
| February 10, 2012 |
NXTM / NxStage Medical, Inc. / WELLS FARGO & COMPANY/MN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) NXSTAGE MEDICAL INC (Name of Issuer) COM (Title of Class of Securities) 67072V103 (CUSIP Number) January 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| January 30, 2012 |
NXTM / NxStage Medical, Inc. / BLAIR WILLIAM & CO/IL - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* NxStage Medical, Inc. (Name of Issuer) Common (Title of Class of Securities) 67072V103 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| January 26, 2012 |
NXTM / NxStage Medical, Inc. / WELLS FARGO & COMPANY/MN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) NXSTAGE MEDICAL INC (Name of Issuer) COM (Title of Class of Securities) 67072V103 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
